Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2007

Bachem Acquires Merck Biosciences’ Business Unit Clinalfa

  • Bachem has acquired the business unit of Merck Biosciences that operates under the brand of Clinalfa®. The transaction includes Clinalfa’s existing customer base, the team headed by Hana Märki, and technical know-how on the Clinalfa products.

    Clinalfa offers a wide range of biologically active peptides and other biologically active products for use in clinical research at scientific institutions and universities across the world. Bachem reports that Clinalfa will substantially expand its range of finished dosage forms for clinical trials and will enable the company to broaden its customer base in this business area, expanding it beyond the existing main target group of biotechnology companies.

    “We are pleased that this acquisition of the Clinalfa® brand enables us to strengthen our range of services in the field of research and to win additional customers, primarily in the university sector and customers who work with so-called challenging agents,” says Walter Isler, head of marketing/sales at Bachem. “This puts us in an even better position to realize our ambition of providing comprehensive support for the clinical development of peptide-based and other biologically active substances with quality products and services.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »